Home » PRO-PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE I TRIAL OF DAVANAT/5-FU IN REFRACTORY CANCER PATIENTS
PRO-PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE I TRIAL OF DAVANAT/5-FU IN REFRACTORY CANCER PATIENTS
Pro-Pharmaceuticals, a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, has completed the enrollment of patients in its Phase I clinical trial to evaluate Davanat alone and in combination with the chemotherapeutic drug 5-Fluorouracil in refractory patients with solid tumors.
With enrollment closed, the company is focused on finishing the treatment and evaluation of patients in the trial.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct